Search
Search
About
Log in
Join
Experiences with
Tepmetko
Posts
Communities
1 public post
Filter results
FDA Approves Tepmetko (tepotinib) for People with Metastatic Non-Small Cell Lung Cancer with MET-Exon 14 Mutation
Tepmetko
(tepotinib) initially received accelerated approval in 2021 based on initial results from the VISION study, which evaluated the use of
Tepmetko
(tepotinib) in people with metastatic NSCLC with a MET-Exon 14 skipping mutation.The new traditional (not accelerated) approval is based on the inclusion
Tepmetko
(tepotinib) initially received accelerated approval in 2021 based on initial results from the VISION study, which evaluated the use of
Tepmetko
(tepotinib) in people with metastatic NSCLC with a MET-Exon 14 skipping mutation.The new traditional (not accelerated) approval is based on the inclusion
Miranda_GO2
Partner
in
Lung Cancer Support
3 months ago
Want to take advantage of all our features? Just log in!
Log in
or
Join
Filter results
Clear filters
Posted in
All communities
Lung Cancer Support
1 result
Sort by
Most Relevant
Newest